drugset / Trial / NCT04894825
Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
Non-randomizedSequentialOpen-labelTreatment
Summary
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.
Timeline
- Start
- 2021-06-11
- Primary completion
- 2024-07-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M108 | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.